Roche Holding AG (RHHBF)
| Previous close | 423.89 |
| Open | 423.89 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 404.00 - 423.89 |
| 52-week range | 320.00 - 423.89 |
| Volume | 72 |
| Avg. volume | 168 |
| Market cap | 330.236B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 22.95 |
| EPS (TTM) | 18.47 |
| Earnings date | N/A |
| Forward dividend & yield | 9.78 (2.31%) |
| Ex-dividend date | 18 Mar 2021 |
| 1y target est | N/A |
- Business Wire
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif., Jun 11, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the latest data from three pivotal Phase III studies of Venclexta® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta in chronic lymphocytic leukemia (CLL) and the possibility of tailor
- GlobeNewswire
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years after completion of a one-year fixed-duration treatment with Venclexta/Venclyxto plus Gazyva/Gazyvaro1New phase III MURANO study data suggested certain genetic risk factors may help tailor treatments for patients with previously treated CLL2A post-hoc analysis from the phase III VIALE-A study in newly diag
- Business Wire
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)
SOUTH SAN FRANCISCO, Calif., Jun 11, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new interim data from two studies of Evrysdi® (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated with another SMA-targeting therapy, including nusinersen and onasemnogene abeparvovec, showed the safety profile of Evrysdi and incr
